Otsuka America Pharmaceutical has selected PantheRx Specialty Pharmacy to distribute Jynarque (tolvaptan), the only FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease.
Brian Griffin will join Diplomat as CEO and chairman, effective June 4, from his position as at Anthem as executive vice president and CEO of its pharmacy benefits manager IngenioRx.
Fred’s will be selling its EntrustRx specialty pharmacy to a CVS Health subsidiary for $40 million, plus the value of the specialty pharmacy’s inventory.
The company received a complete response letter from the Food and Drug Administration regarding the biosimilar, meaning it won’t be approving its application in its submitted form.
McKesson ideaShare 2018 will showcase how to implement and manage new possible revenue streams for independent operators, such as immunization programs, front-end solutions and specialty programs.
With its newly minted pharmacy benefit management segment up and running and its CEO search nearing an end, Diplomat hit record revenues in Q1, but still swung to a $500,000 loss.
The company posted a net loss of $139.3 million for fiscal year 2017 and said it is exploring its options for its retail pharmacy business as it looks to unload the specialty pharmacy business and portions of its real estate portfolio.
The company said the specialty pharmacy launch was designed to offer customized, convenient care for patients with such conditions as cancer, hepatitis, multiple sclerosis and Crohn’s disease.